BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a wholly-owned subsidiary of Parent.

北京，2023年10月11日（GLOBE NEWSWIRE）-Genetron Holdings Limited（“Genetron Health”或“Company”，纳斯达克：GTH），是中国领先的精准肿瘤学平台公司，专门提供分子谱分析测试，早期癌症筛查产品和伴随诊断开发，今天宣布，它已与New Genetron Holding Limited（“Parent”）和Genetron New Co Limited（“Merger Sub”）（母公司的合资子公司）签订了明确的协议和合并计划（“合并协议”）。

Pursuant to the Merger Agreement and subject to the terms and conditions thereof, Merger Sub will merge with and into the Company, with the Company continuing as the surviving entity and becoming a wholly-owned subsidiary of Parent (the “Merger”), in a transaction implying an equity value of the Company of approximately US$126.0 million.

根据合并协议并根据其条款和条件，合并子公司将与本公司合并并进入本公司，本公司继续作为幸存实体并成为母公司的合资子公司（“合并”），交易意味着本公司股权约为1.260亿美元。

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each ordinary share, par value US$0.00002 per share, of the Company (each, a “Share”) issued, outstanding and not represented by American depositary share of the Company (each, an “ADS,” representing five1 Shares) immediately prior to the Effective Time, other than the Excluded Shares and the Dissenting Shares (each as defined in the Merger Agreement), will be cancelled and cease to exist, in exchange for the right to receive US$0.272 in cash per Share without interest (the “Per Share Merger Consideration”), and each ADS, issued and outstanding immediately prior to the Effective Time, other than ADSs representing the Excluded Shares, together with each Share represented by such ADS, will be cancelled and cease to exist, in exchange for the right to receive US$1.36 in cash per ADS (or US$4.08 in cash per .

根据合并协议条款，在合并生效时（“生效时间”），本公司（各自为“股份”）发行，已发行，尚未发行的每股普通股，par值为0.00002美元，不代表本公司的美国存款人股份（各自为“广告”，代表五股股份），除了被排除的股份和异议股（均为合并协议中定义的股份）将被取消并不再存在，以换取无权益获得0.272美元现金的权利（“股权合并考虑”），以及在生效前立即发行和发行的每个广告，不包括代表被排除股份的ADS，连同此类广告代表的每股股份将被取消并不再存在，以换取每次广告获得1.36美元现金（或每笔现金4.08美元）的权利。